By CAC2 Member Autumn Gentry, MACC Fund This collaborative state advocacy effort was due to the dedicated work of a pair of CAC2 members in
Assorted News from the Last Week: Early interventions may improve long-term academic achievement in young childhood brain tumor survivors. Early onset psychosis in a pediatric
Assorted News from the Last Week: The NCI Budget Fact Book summarizes the distribution of the fiscal year 2023 budget among the various NCI research
Assorted News from the Last Week: Lifestyle habits can alleviate the effects of cancer treatment in children. A study into precision medicine for high-risk Neuroblastoma
Assorted News from the Last Week: Congratulations to CAC2 Members Autumn Gentry (MACC Fund, Inc) and Mariah Forster Olson (Neuroblastoma Children’s Cancer Society) with inspiration
Assorted News from the Last Week: CAC2 Supporting Member Day One Biopharmaceutical and Ipsen unveiled an ex-U.S. licensing agreement for tovorafenib (approved as Ojemda in
At CAC2 we love to celebrate when our members work together. We offer congratulations to Supporting Organization Day One Biopharmaceuticals and CAC2 member authors and
Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals and CAC2 member authors and reviewers who contributed to the white
Assorted News from the Last Week: Psychological and ethical issues raised by genomic testing in paediatric care pathway, a qualitative analysis with parents and childhood
The NCI Council of Research Advocates met virtually on June 26 and heard the latest legislative report, with updates on appropriations, cancer-related legislation, and other
